U.S. Tardive Dyskinesia Treatment Market - 2024 - 2031

Market The U.S. Tardive Dyskinesia Treatment market is expected to reach US$ 6417.43 million in 2031, from its recorded value of US$ 3061.64 million in 2023, exhibiting a CAGR of 9.8% during the forecast period.

Tardive dyskinesia (TD) is a neurological disease noted by involuntary, repetitive movements. The disease often results from long-term use of certain medications, particularly antipsychotics, prescribed for psychiatric conditions like schizophrenia and bipolar disorder.

Symptoms include grimacing, tongue movements, lip smacking, puckering and pursing of the lips, and rapid eye blinking. In some cases, there are also rapid movements of the arms, legs, and trunk.

The major treatment plan involves reducing the dose or discontinuing the medication causing the symptoms, under the direction of a healthcare professional to avoid increasing the underlying condition.

Alternatives with a lower risk of causing TD, such as atypical antipsychotics like clozapine or quetiapine, may be considered.

Supportive therapies such as physical, speech, and occupational therapy play a crucial role in managing symptoms and enhancing daily functioning. Additionally, lifestyle modifications, including stress management techniques and nutritional support, can help mitigate the impact of TD.

Market Dynamics

Increasing clinical approvals

Increasing clinical approvals significantly drive the tardive dyskinesia (TD) treatment market by enhancing the availability and accessibility of effective treatment options. Regulatory approvals from authoritative bodies like the FDA provide validation of a drug's safety and efficacy, increasing the confidence of healthcare providers in prescribing these medications. This can lead to higher prescription rates and market growth.

For instance, in 2024, the Food and Drug Administration (FDA) approved Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) extended-release tablets, a new once-daily formulation of Austedo for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) in adults. Austedo XR is now available in four tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

The new formulation may help improve treatment adherence and simplify medication management for patients with TD and chorea associated with HD. Through the Teva Shared Solutions program, the company provides support to patients and providers through access, affordability, and adherence strategies.

Additionally, in 2024, the US Food and Drug Administration approved Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). Ingrezza Sprinkle is a new oral granules formulation of the medication, which is currently approved for the treatment of TD. The new formulation was also approved for the treatment of chorea associated with Huntington's disease in adults.

Ingrezza was the first drug approved to treat TD in 2017. At the time it was granted Fast Track, Priority Review, and Breakthrough Therapy designations.

Market Segment Analysis

The USA Tardive Dyskinesia treatment market is segmented based on Drug, Distribution Channel.

Valbenazine

Valbenazine in the U.S. tardive dyskinesia treatment market was valued at US$ 1799.63 million in 2023 and is estimated to reach US$ 3729.67 million by 2031, growing at a CAGR of 9.7% during the forecast period from 2024-2031.

Valbenazine selectively inhibits VMAT2, with little to no affinity for VMAT1 or other monoamine receptors. It metabolizes slowly, has less peak-to-trough variations in plasma levels than TBZ, and has a half-life of approximately 20 hours, allowing for a once-daily administration. Genotyping is not required but dosing adjustments are recommended in the presence of CYP 2D6 or CYP 3A4 modulators.

Valbenazine’s mechanism of action is mediated through the reversible inhibition of VMAT2 in the treatment of tardive dyskinesia. VMAT2 is selective to the central nervous system and is responsible for the transport and recycling of neurotransmitters across the synapse. The inhibition of VMAT2 augments neurotransmitter degradation and results in presynaptic neurotransmitter depletion, particularly of dopamine.

Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (tardive dyskinesia) and is at various stages of development in other countries for tardive dyskinesia.

Valbenazine has been approved in the USA since 2017 for the treatment of tardive dyskinesia (tardive dyskinesia), involuntary movements that stem from the use of medications known as neuroleptics or antipsychotics. Antipsychotics are taken by many people worldwide to treat the psychiatric and behavioral symptoms of bipolar disorder, schizophrenia, and other diseases (including Huntington’s disease).

The advantages of valbenazine include rapid onset of effect within two weeks of treatment initiation. INGREZZA is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

Market Segmentation

By Drug
• Valbenazine
• Deutetrabenazine
• Tetrabenazine
• Clonazepam
• Amantadine
• Others

By Distribution channel
• Hospital and Speciality Pharmacies
• Retail Pharmacies
• Others

Major Key players
• Teva Pharmaceutical Industries Ltd
• Neurocrine Biosciences, Inc.
• Lupin Limited
• Accord Healthcare, Inc.
• Mitsubishi Corporation
• Dr. Reddy’s Laboratories Limited
• BIONPHARMA INC.
• Slate Run Pharmaceuticals
• Aurobindo Pharma Limited
• Apotex Inc.

The U.S. tardive dyskinesia treatment market report would provide access to approx. 42 market data tables, 42 figures, and 123 pages.